Nadroparin calcium
As of the edition of 20 October 2026, Nadroparin calcium is an oligosaccharide: marketed, first approved in 1985 (FR); acts on SERPINC1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1997
- Kind
- Oligosaccharide
- Brand name
- Fraxiparine
- First approved
- 4 March 1985 (FR)
- Approvals on record
- 2 in 2 regions
- Holder of the most recent approval
- ASPEN PHARMACARE CANADA INC.; 2 holders in all
- Registered trials
- 25, 2 stopped early
- Disease areas
- Heart and blood vessels; Digestive system; Cancer; Lungs and airways; Urinary and reproductive; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SERPINC1 | Antithrombin-III | P01008 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 4 | 0 | 2 |
| Phase 3 | 5 | 3 | 0 | 0 |
| Phase 4 | 12 | 5 | 0 | 0 |
| All trials | 25 |